3634 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 12
Qu et al.
(7) Wikberg, J. E. S.; Mutulis, F. Targeting melanocortin receptors: an
approach to treat weight disorders and sexual dysfunction. Nat. ReV.
Drug DiscoVery 2008, 7, 307–323.
(8) Fan, W.; Boston, B. A.; Kesterson, R. A.; Hruby, V. J.; Cone, R. D.
Role of the melanocortinergic neurons in feeding and the agouti obesity
syndrome. Nature 1997, 385, 165–168.
(30) Martin, W. J.; McGowan, E.; Cashen, D. E.; Gantert, L. T.; Drisko,
J. E.; Hom, G. J.; Nargund, R.; Sebhat, I.; Howard, A. D.; Van der
Ploeg, L. H. T.; MacIntyre, D. E. Activation of melanocortin MC4
receptors increases erectile activity in rats ex copula. Eur. J. Phar-
macol. 2002, 454, 71–79.
(31) Chaki, S.; Okubo, T. Melanocortin-4 receptor antagonists for the
treatment of depression and anxiety disorders. Curr. Top. Med. Chem.
2007, 7, 1145–1151.
(32) Van der Kraan, M.; Adan, R. A.; Entwistle, M. L.; Gispen, W. H.;
Burbach, J. P.; Tatro, J. B. Expression of melanocortin-5 receptor in
secretory epithelia supports a functional role in exocrine and endocrine
glands. Endocrinology 1998, 139, 2348–2355.
(33) Chen, W. B.; Kelly, M. A.; Opitz Araya, X.; Thomas, R. E.; Low,
M. J.; Cone, R. D. Exocrine gland dysfunction in MC5-R deficient
mice: evidence for coordinated regulation of exocrine gland function
by melanocortin peptides. Cell 1997, 91, 789–798.
(34) Caldwell, H. K.; Lepri, J. J. Disruption of the fifth melanocortin
receptor alters the urinary excretion of aggression-modifying pher-
mones in male house mice. Chem. Senses 2002, 27, 91–94.
(35) Palucki, B. L.; Park, M. K.; Nargund, R. P.; Tang, R.; MacNeil, T.;
Weinberg, D. H.; Vongs, A.; Rosenblum, C. I.; Doss, G. A.; Miller,
R. R.; Stearns, R. A.; Peng, Q.; Tamvakopoulos, C.; Van der Ploeg,
L. H. T.; Patchetta, A. A. 2-Piperazinecarboxamides as potent and
selective melanocortin subtype-4 receptor agonists. Bioorg. Med.
Chem. Lett. 2005, 15, 1993–1996.
(36) (a) Coll, A. P. Effects of pro-opiomelanocortin (POMC) on food intake
and body weight: mechanisms and therapeutic potential. Clin. Sci.
2007, 113, 171–182. (b) Van der Ploeg, L. H.; Kanatani, A.; MacNeil,
D.; Ming, F. T.; Strack, A.; Nargund, R.; Guan, X. M. Design and
synthesis of (ant)-agonists that alter appetite and adiposity. Prog. Brain
Res. 2006, 153, 107–118.
(9) Vergoni, A. V.; Poggioloi, R.; Bertolini, A. Corticotropin inhibits food
intake in rats. Neuropeptides 1986, 7, 153–158.
(10) Vergoni, A. V.; Poggioloi, R.; Marrama, D.; Bertolini, A. Inhibition
of feeding by ACTH-(1-24): behavioral and pharmacological aspects.
Eur. J. Pharmacol. 1990, 179, 347–355.
(11) Ramos, E. J. B.; Meguid, M. M.; Campos, A. C. L.; Coelho, J. C. U.
Neuropeptide Y, R-melanocyte-stimulating hormone, and monoamines
in food intake regulation. Nutrition 2005, 21, 269–279.
(12) Yang, Y. K.; Harmon, C. M. Recent developments in our understanding
of melanocortin system in the regulation of food intake. Obes. ReV.
2003, 4, 239–248.
(13) Ellacott, K. L. J.; Cone, R. D. The central melanocortin system and
the integration of short- and long-term regulators of energy homeo-
stasis. Recent Prog. Horm. Res. 2004, 59, 395–408.
(14) Zimanyi, I. A.; Pelleymounter, M. A. The role of melanocortin peptides
and receptors in regulation of energy balance. Curr. Pharm. Des. 2003,
9, 627–641.
(15) Morgan, C.; Thomas, R. E.; Cone, R. D. Melanocortin-5 receptor
deficiency promotes defensive behavior in male mice. Horm. BehaV.
2004, 45, 58–63.
(16) Mogil, J. S.; Wilson, S. G.; Chesler, E. J.; Rankin, A. L.; Nemmani,
K. V. S.; Lariviere, W. R.; Groce, M. K.; Wallace, M. R.; Kaplan, L.;
Staud, R.; Ness, T. J.; Glover, T. L.; Stankova, M.; Mayorov, A. V.;
Hruby, V. J.; Grisel, J. E.; Fillingim, R. B. The melanocortin-1 receptor
gene mediates female-specific mechanisms of analgesia in mice and
humans. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4867–4872.
(17) Vrinten, D. H.; Kalkman, C. J.; Adan, R. A. H.; Gispen, W. H.
Neuropathic pain: a possible role for the melanocortin system? Eur.
J. Pharmacol. 2001, 429, 61–69.
(18) Mogil, J. S.; Ritchie, J.; Smith, S. B.; Strasburg, K.; Kaplan, L.;
Wallace, M. R.; Romberg, R. R.; Bijl, H.; Sarton, E. Y.; Fillingim,
R. B.; Dahan, A. Melanocortin-1 receptor gene variants affect pain
and µ-opioid analgesia in mice and humans. J. Med. Genet. 2005, 42,
583–587.
(19) Mountjoy, K. G. Cloning of the Melanocortin Receptors. In Melano-
cortin Receptors; Cone, R. D., Ed.; Humana Press: Totowa, NJ, 2000;
pp 209-235.
(20) Vaudry, H., Eberle, A. N., Eds. The Melanotropic Peptides; Annals
of the New York Academy of Sciences, Vol. 680; The New York
Academy of Sciences: New York, 1993; pp 1-687.
(21) Maaser, C., Kannengesser, K., Kucharzik, T., Eds. Role of the
Melanocortin System in Inflammation; Annals of the New York
Academy of Science, Vol. 1072; The New York Academy of Sciences:
New York, 2006; 123-134.
(22) Catania, A. The melanocortin system in leukocyte biology. J. Leukocyte
Biol. 2007, 81, 383–392.
(23) Gispen, W. H.; Isaacson, R. L. ACTH-induced excessive grooming
in the rat. Pharmacol. Ther. 1981, 12, 209–246.
(24) Gantz, I.; Fong, T. M. The melanocortin system. Am. J. Physiol.:
Endocrinol. Metab. 2003, 284, E468–E474.
(25) Chhajlani, B. Distribution of cDNA for melanocortin receptor subtypes
in human tissues. Biochem. Mol. Biol. Int. 1996, 38, 73–80.
(26) Cone, R. D., Ed. The Melanocortin Receptors; Humana Press: Totowa,
NJ, 2000; pp 1-554.
(37) Lam, D. D.; Farooqi, I. S.; Heisler, L. K. Melanocortin receptors as
targets in the treatment of obesity. Curr. Top. Med. Chem. 2007, 7,
1098–1110.
(38) (a) Chaki, S.; Okuyama, S. Involvement of melanocortin-4 receptor
in anxiety and depression. Peptides 2005, 26, 1952–1964. (b) Foster,
A. C.; Chen, C. Melanocortin-4 receptor antagonists as potential
therapeutics in the treatment of cachexia. Curr. Top. Med. Chem. 2007,
7, 1131–1136. (c) Chen, C.; Jiang, W.; Tucci, F.; Tran, J. A.; Fleck,
B. A.; Hoare, S. R.; Joppa, M.; Markison, S.; Wen, J.; Sai, Y.; Johns,
M.; Madan, A.; Chen, T.; Chen, C. W.; Marinkovic, D.; Arellano,
M.; Saunders, J.; Foster, A. C. Discovery of 1-[2-[(1S)-(3-dimethy-
laminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-
methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active
antagonist of the melanocortin-4 receptor for the potential treatment
of cachexia. J. Med. Chem. 2007, 50, 5249–5252.
(39) Hadley, M. E.; Dorr, R. T. Melanocortin peptide therapeutics: historical
milestones, clinical studies and commercialization. Peptides 2006, 27,
921–930.
(40) Shadiack, A. M.; Sharma, S. D.; Earle, D. C.; Spana, C.; Hallam,
T. J. Melanocortins in the treatment of male and female sexual
dysfunction. Curr. Top. Med. Chem. 2007, 7, 1137–1144.
(41) Mcnulty, J. C.; Jackson, P. J.; Thompson, D. A.; Chai, B.; Gantz, J.;
Barsh, G. S.; Dawson, P. E.; Millhauser, G. L. Structures of the agouti
signaling protein. J. Mol. Biol. 2005, 346, 1059–1070.
(42) Ollmann, M. M.; Wilson, B. D.; Yang, Y. K.; Kerns, J. A.; Chen, Y.;
Gantz, I.; Barsh, G. S. Antagonism of central melanocortin receptors
in vitro and in vivo by agouti-related protein. Science 1997, 278, 135–
138.
(43) Yang, Y. K.; Fong, T. M.; Dickinson, C. J.; Mao, C.; Li, J. Y.; Tota,
M. R.; Mosley, R.; Van der Ploeg, L. H. T.; Gantz, I. Molecular
determinants of ligand binding to the human melanocortin-4 receptor.
Biochemistry 2000, 39, 14900–14911.
(44) Haskell-Luevano, C.; Cone, R. D.; Monck, E. K.; Wan, Y. P. Structure
activity studies of the melanocortin-4 receptor by in vitro mutagenesis:
identification of agouti-related protein (AGRP), melanocortin agonist
and synthetic peptide antagonist interaction determinants. Biochemistry
2001, 40, 6164–6179.
(45) Wilczynski, A.; Wang, X. S.; Joseph, C. G.; Xiang, Z.; Bauzo, R. M.;
Scott, J. W.; Sorensen, N. B.; Shaw, A. M.; Millard, W. J.; Richards,
N. G.; Haskell-Luevano, C. Identification of putative agouti-related
protein(87-132)-melanocortin-4 receptor interactions by homology
molecular modeling and validation using chimeric peptide ligands.
J. Med. Chem. 2004, 47, 2194–2207.
(27) Raffin-Sanson, M. L.; Bertherat, J. MC3 and MC4 receptors:
complementary role in weight control. Eur. J. Endocrinol. 2001, 144,
207–208.
(28) (a) Marks, D. L.; Hruby, V. J.; Brookhart, G.; Cone, R. D. The
regulation of food intake by selective stimulation of the type 3
melanocortin receptor (MC3R). Peptides 2006, 27, 259–264. (b) Lee,
M.; Kim, A.; Conwell, I. M.; Hruby, V. J.; Mayorov, A.; Cai, M.;
Wardlaw, S. L. Effects of selective modulation of the central
melanocortin-3-receptor on food intake and hypothalamic POMC
expression. Peptides 2008, 29, 440–447.
(29) (a) Getting, S. J. Melanocortin peptides and their receptors: new targets
for anti-inflammatory therapy. Trends Pharmacol. Sci. 2002, 23, 447–
449. (b) Getting, S. J.; Christian, H. C.; Flower, R. J.; Perretti, M.
Activation of melanocortin type 3 receptor as a molecular mechanism
for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis
Rheum. 2002, 46, 2765–2775. (c) Getting, S. J.; Christian, H. C.; Lam,
C. W.; Gavins, F. N. E.; Flower, R. J.; Schio¨th, H. B.; Perretti, M.
Redundancy of a functional melanocortin 1 receptor in the anti-
inflammatory actions of melanocortin peptides: studies in the recessive
yellow (e/e) mouse suggest an important role for melanocortin 3
receptor. J. Immunol. 2003, 170, 3323–3330.
(46) Ying, J.; Koever, K. E.; Gu, X.; Han, G.; Trivedi, D.; Kavarana, M. J.;
Hruby, V. J. Solution structures of cyclic melanocortin agonists and
antagonists by NMR. Biopolymers 2003, 7, 696–716.
(47) (a) Pettit, G. R.; Srirangam, J. K.; Herald, D. L.; Xu, J.; Boyd, M. R.;
Cichacz, Z.; Kamano, Y.; Schmidt, J. M.; Erickson, K. L. Isolation
and crystal structure of stylopeptide 1, a new marine porifera
cycloheptapeptide. J. Org. Chem. 1995, 60, 8257–8261. (b) Imperiali,
B.; Moats, R. A.; Fisher, S. L.; Prins, T. J. A conformational study of
peptides with the general structure Ac-L-Xaa-Pro-D-Xaa-L-Xaa-NH2: